Based on the Verrica Pharmaceuticals Inc stock forecast from 2 analysts, the average analyst target price for Verrica Pharmaceuticals Inc is USD 4.00 over the next 12 months. Verrica Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Verrica Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 7 negative signals. At the last closing, Verrica Pharmaceuticals Inc’s stock price was USD 0.48. Verrica Pharmaceuticals Inc’s stock price has changed by -8.70% over the past week, -18.12% over the past month and -92.95% over the last year.
No recent analyst target price found for Verrica Pharmaceuticals Inc
No recent average analyst rating found for Verrica Pharmaceuticals Inc
Company Overview Verrica Pharmaceuticals Inc
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, engages in the development and sales of medications for the treatment of skin diseases in the United States. The company's product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania. Read Less
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, engages in the development and sales of medications for the treatment of skin diseases in the United States. The company's product pipeline comprises YCANTH (VP-102), which is in phase III clinical t...Read More
Frequently Asked Questions About Verrica Pharmaceuticals Inc (VRCA) Stock
Based on ratings from 2 analysts Verrica Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on VRCA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for VRCA is USD 4.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on VRCA's stock to indicate if its overvalued.
The last closing price of VRCA's stock was USD 0.48.
The most recent market capitalization for VRCA is USD 0.04B.
Based on targets from 2 analysts, the average taret price for VRCA is projected at USD 4.00 over the next 12 months.
This means that VRCA's stock price may go up by +726.45% over the next 12 months.
We can't find any ETFs which contains Verrica Pharmaceuticals Inc's stock.
As per our most recent records Verrica Pharmaceuticals Inc has 71 Employees.
Verrica Pharmaceuticals Inc's registered address is 44 West Gay Street, West Chester, PA, United States, 19380.
You can get more information about it from Verrica Pharmaceuticals Inc's website at https://www.verrica.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Verrica Pharmaceuticals Inc (VRCA) Stock
Based on ratings from 2 analysts Verrica Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 2 buy, sell and hold ratings.
Unfortunately we do not have enough data on VRCA's stock to indicate if its a good dividend stock.
Based on targets from 2 analysts, the average taret price for VRCA is USD 4.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 3.
Unfortunately we do not have enough data on VRCA's stock to indicate if its overvalued.
The last closing price of VRCA's stock was USD 0.48.
The most recent market capitalization for VRCA is USD 0.04B.
Based on targets from 2 analysts, the average taret price for VRCA is projected at USD 4.00 over the next 12 months.
This means that VRCA's stock price may go up by +726.45% over the next 12 months.
We can't find any ETFs which contains Verrica Pharmaceuticals Inc's stock.
As per our most recent records Verrica Pharmaceuticals Inc has 71 Employees.
Verrica Pharmaceuticals Inc's registered address is 44 West Gay Street, West Chester, PA, United States, 19380.
You can get more information about it from Verrica Pharmaceuticals Inc's website at https://www.verrica.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for VRCA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
